China vs India: The number of people with susceptibility test result for rifampicin
China
79.92
in 2021
India
76.27
in 2021
China rank
95th
India rank
98th
The number of people with susceptibility test result for rifampicin over time
- China
- India
How they compare
China currently reports 79.92 against 76.27 in India, a difference of 3.65.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was China ahead.
China ranks 95th and India ranks 98th of 146 countries.
Across the 2 decades both report, China averaged higher in 1 and India in 1.
Head to head by decade
| Decade | China | India | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 59.88 | 51.98 | 7.9 | China |
| 2020s | 81.69 | 87.02 | 5.33 | India |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, China or India?
- China, at 79.92 against 76.27 in India as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between China and India?
- 3.65, with China ahead.
- How many years of comparable data are there for China and India?
- 5 years are reported by both, from 2017 to 2021.
- How do China and India rank globally for the number of people with susceptibility test result for rifampicin?
- China ranks 95th and India ranks 98th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.